TNFRSF17 and neoplasm: A 2025 abstract described a BCMA-mRNA vaccine packaged in LNPs with the toll-like receptor-3 agonist poly(I:C); the vaccine was taken up by dendritic cells, elicited BCMA-specific cytotoxic T cells and reduced tumor growth in mouse models, suggesting that mRNA vaccines might be used to prime anti-MM immunity [147].